This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitat Heidelberg. Active years: 2014-2018.
Company Filing History:
3 out of 159 
2 out of 63 
Years Active: 2014-2018
Title: Corinna Koch: Innovator in Cancer Research
Introduction
Corinna Koch is a prominent inventor based in Einhausen, Germany. She has made significant contributions to the field of cancer research through her innovative work on chromene derivatives. With a total of 3 patents, her research focuses on modulating the Wnt signaling pathway, which plays a crucial role in cancer progression.
Latest Patents
Corinna's latest patents include groundbreaking compounds that serve as Wnt pathway antagonists. These compounds, described by the formula (IIc), feature components where X and X can independently be nitrogen or carbon, and R may vary. Additionally, Y components can also be nitrogen or carbon, with the possibility of having up to three Y components as nitrogen. These compounds, along with their solvates, hydrates, and pharmaceutically acceptable salts, are designed for use in modulating Wnt signaling pathway activity and are intended as medicaments, particularly for cancer treatment.
Career Highlights
Throughout her career, Corinna has worked with esteemed institutions such as the Deutsches Krebsforschungszentrum and Ruprecht-Karls-Universität Heidelberg. Her research has not only advanced scientific understanding but has also paved the way for potential therapeutic applications in oncology.
Collaborations
Corinna has collaborated with notable colleagues, including Florian Fuchs and Daniel Gilbert. These partnerships have enriched her research and contributed to the development of innovative solutions in cancer treatment.
Conclusion
Corinna Koch's work exemplifies the impact of innovation in the medical field, particularly in cancer research. Her contributions through patents and collaborations highlight her dedication to advancing healthcare solutions.